Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma
Biliary tract carcinoma（BTC） is a highly malignant tumor with a poor prognosis. Although radical surgical resection remains the only curative treatment, only 20% of patients are eligible for curative resection. In recent years, comprehensive treatments combining chemotherapy with immunotherapy and t...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Surgery Concepts & Practice
2025-03-01
|
| Series: | Waike lilun yu shijian |
| Subjects: | |
| Online Access: | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1751876334910-925139371.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850085170893291520 |
|---|---|
| author | QI Zhong, CHENG Shi |
| author_facet | QI Zhong, CHENG Shi |
| author_sort | QI Zhong, CHENG Shi |
| collection | DOAJ |
| description | Biliary tract carcinoma（BTC） is a highly malignant tumor with a poor prognosis. Although radical surgical resection remains the only curative treatment, only 20% of patients are eligible for curative resection. In recent years, comprehensive treatments combining chemotherapy with immunotherapy and targeted therapy, have become a key strategy in the current biological benefit-dominated therapeutic paradigm for BTC. However, the efficacy of these multimodal treatments remains suboptimal and heavily relies on precise individualized drug screening and response evaluation. The emerging tumor organoid technology faithfully recapitulates the histomorphological features and growth behavior of tumors, providing a novel platform for screening tumor-specific biomarkers. By enhancing tumor identification and margin delineation, this approach facilitates precise preoperative staging and optimize surgical planning. Furthermore, drug sensitivity testing based on patient-derived organoids enables personalized treatment strategies, demonstrating significant clinical value in improving comprehensive therapy for BTC. |
| format | Article |
| id | doaj-art-c5f525ca790146a19f47983b62fd11d4 |
| institution | DOAJ |
| issn | 1007-9610 |
| language | zho |
| publishDate | 2025-03-01 |
| publisher | Editorial Office of Journal of Surgery Concepts & Practice |
| record_format | Article |
| series | Waike lilun yu shijian |
| spelling | doaj-art-c5f525ca790146a19f47983b62fd11d42025-08-20T02:43:47ZzhoEditorial Office of Journal of Surgery Concepts & PracticeWaike lilun yu shijian1007-96102025-03-0130210110410.16139/j.1007-9610.2025.02.02Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinomaQI Zhong, CHENG Shi0Department of General Surgery，Beijing Tiantan Hospital，Capital Medical University, Beijing 100070,ChinaBiliary tract carcinoma（BTC） is a highly malignant tumor with a poor prognosis. Although radical surgical resection remains the only curative treatment, only 20% of patients are eligible for curative resection. In recent years, comprehensive treatments combining chemotherapy with immunotherapy and targeted therapy, have become a key strategy in the current biological benefit-dominated therapeutic paradigm for BTC. However, the efficacy of these multimodal treatments remains suboptimal and heavily relies on precise individualized drug screening and response evaluation. The emerging tumor organoid technology faithfully recapitulates the histomorphological features and growth behavior of tumors, providing a novel platform for screening tumor-specific biomarkers. By enhancing tumor identification and margin delineation, this approach facilitates precise preoperative staging and optimize surgical planning. Furthermore, drug sensitivity testing based on patient-derived organoids enables personalized treatment strategies, demonstrating significant clinical value in improving comprehensive therapy for BTC.https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1751876334910-925139371.pdf|biliary tract carcinoma（btc）|organoid|biological benefit|comprehensive treatments |
| spellingShingle | QI Zhong, CHENG Shi Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma Waike lilun yu shijian |biliary tract carcinoma（btc）|organoid|biological benefit|comprehensive treatments |
| title | Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma |
| title_full | Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma |
| title_fullStr | Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma |
| title_full_unstemmed | Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma |
| title_short | Role of organoid research in the biological benefit-dominated diagnosis and treatment of biliary tract carcinoma |
| title_sort | role of organoid research in the biological benefit dominated diagnosis and treatment of biliary tract carcinoma |
| topic | |biliary tract carcinoma（btc）|organoid|biological benefit|comprehensive treatments |
| url | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1751876334910-925139371.pdf |
| work_keys_str_mv | AT qizhongchengshi roleoforganoidresearchinthebiologicalbenefitdominateddiagnosisandtreatmentofbiliarytractcarcinoma |